Cabo Verde
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.097–0.19) 30 (19–39)
Mortality (HIV+TB only) 0.015 (0.012–0.018) 3 (2.5–3.6)
Prevalence  (includes HIV+TB) 1.2 (0.63–1.9) 238 (125–386)
Incidence  (includes HIV+TB) 0.71 (0.64–0.81) 143 (127–161)
Incidence (HIV+TB only) 0.048 (0.043–0.053) 9.7 (8.5–11)
Case detection, all forms (%) 42 (38–48)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
5 (0–13) 7 (0–13)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 183   21
Pulmonary, clinically diagnosed 57   0
Extrapulmonary 41   0
       
Total new and relapse 302    
Previously treated, excluding relapses 12    
Total cases notified 314    
Among 183 new cases:
2 (1%) cases aged under 15 years; male:female ratio: 2.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 (3%) 0 (0%) 5
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 290 (92)
HIV-positive TB patients 24 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 24 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 24 (100)
HIV-positive people screened for TB 420  
HIV-positive people provided with IPT 420  
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 64
HIV-positive TB cases, all types, registered in 2012 67
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.2
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 85%
% Funded internationally 15%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-27 Data: www.who.int/tb/data